Skip Navigation


Cardiovascular Research Advance Access originally published online on July 22, 2008
Cardiovascular Research 2008 80(2):263-270; doi:10.1093/cvr/cvn195
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
80/2/263    most recent
cvn195v2
cvn195v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Korpisalo, P.
Right arrow Articles by Ylä-Herttuala, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korpisalo, P.
Right arrow Articles by Ylä-Herttuala, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs

Petra Korpisalo1,{dagger}, Tuomas T. Rissanen1,{dagger}, Timo Bengtsson1, Timo Liimatainen1, Svetlana Laidinen1, Henna Karvinen1, Johanna E. Markkanen1, Olli H. Gröhn2 and Seppo Ylä-Herttuala1,3,4,*

1 Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland
2 Department of Neurobiology, A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland
3 Department of Medicine, University of Kuopio, Kuopio, Finland
4 Gene Therapy Unit, University of Kuopio, Kuopio, Finland

* Corresponding author. Tel: +358 17 162075; fax: +358 17 163751. E-mail address: seppo.ylaherttuala{at}uku.fi

Aims: We investigated the effects of angiogenic gene therapy with adenoviral placental growth factor131 (AdPlGF) on aerobic capacity and exercise tolerance in a rabbit hindlimb ischaemia model. We also assessed whether strong angiogenic changes such as capillary arterialization and formation of artery-venous shunts compromise oxygen transport to target tissues resulting in suboptimal therapeutic efficacy.

Methods and results: Hindlimb ischaemia was surgically induced in New Zealand White rabbits (n = 20) that a day later received intramuscular (i.m.) AdPlGF or AdLacZ (3x1011vp) gene transfer (GT). Corresponding GTs were also done in healthy non-ischaemic rabbits (n = 10). Muscle energy metabolism and skeletal muscle perfusion were studied non-invasively before GT and at 6 and 28 days using 31P-magnetic resonance spectroscopy and contrast pulse sequence ultrasound, respectively. Oedema was quantified using modified Miles assay at sacrifice. AdPlGF increased perfusion 7.8-fold and improved aerobic capacity of ischaemic limbs 45% compared with AdLacZ controls (P < 0.05) at 6 days. In non-ischaemic limbs, strong angiogenic response to GT, including capillary arterialization and acute oedema, did not impair muscle energy metabolism.

Conclusion: This study shows that proangiogenic gene therapy can significantly improve performance of ischaemic limbs and supports the concept of therapeutic angiogenesis for the treatment of patients with ischaemia.

KEYWORDS Gene therapy; Energy metabolism; Magnetic resonance spectroscopy; Vascular endothelial growth factors; Angiogenesis

Time for primary review: 52 days

{dagger} First two Authors contributed equally to this work


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.